RATIONALE: Patients with cystic fibrosis (CF) have high rates of vitamin D insufficiency. The relation between vitamin D status and inflammation in patients with CF is poorly understood. OBJECTIVES: To determine the prevalence of vitamin D deficiency and insufficiency in a young CF population and to examine correlations between vitamin D status, disease severity, and inflammatory markers. METHODS: This was a retrospective chart review of patients with CF under the age of 12 years. Serum laboratory parameters, growth indices, pancreatic status, CFTR genetics, medications, microbiology, and presence of CF-related comorbidities were collected for patients who had fat-soluble vitamin levels measured between January 1, 2009 and December 31, 2011. Vitamin D deficiency was defined as a serum 25(OH)D less than 20 ng/ml and insufficiency as serum 25(OH)D 20 to 29.9 ng/ml. Associations between serum vitamin D concentration and clinical/inflammatory markers were assessed using Chi-square and t tests. MEASUREMENTS AND MAIN RESULTS: Data were collected for 148 children. The mean serum 25(OH)D concentration was 32.4 ng/ml (SD, 8.9). Seven percent (10 of 148) were vitamin D deficient, and 36% (53 of 148) were vitamin D insufficient. Among the pancreatic-sufficient patients, 50% (14 of 28) were vitamin D insufficient/deficient, whereas among pancreatic-insufficient patients, 41% (49 of 120) were vitamin D insufficient/deficient. Pseudomonas aeruginosa was a more common pathogen in the patients who were vitamin D insufficient/deficient (18 of 63 vs. 11 of 85, P = 0.018). There was no difference between vitamin D-sufficient versus -insufficient groups in terms of other bacterial colonization or inflammatory markers. CONCLUSIONS: Overall, vitamin D insufficiency is common among young children with CF. Vitamin D insufficiency is prevalent even in children who are pancreatic sufficient. In this population, vitamin D insufficiency is associated with a history of Pseudomonas colonization but not with classic markers of systemic inflammation.
RATIONALE: Patients with cystic fibrosis (CF) have high rates of vitamin Dinsufficiency. The relation between vitamin D status and inflammation in patients with CF is poorly understood. OBJECTIVES: To determine the prevalence of vitamin Ddeficiency and insufficiency in a young CF population and to examine correlations between vitamin D status, disease severity, and inflammatory markers. METHODS: This was a retrospective chart review of patients with CF under the age of 12 years. Serum laboratory parameters, growth indices, pancreatic status, CFTR genetics, medications, microbiology, and presence of CF-related comorbidities were collected for patients who had fat-soluble vitamin levels measured between January 1, 2009 and December 31, 2011. Vitamin D deficiency was defined as a serum 25(OH)D less than 20 ng/ml and insufficiency as serum 25(OH)D 20 to 29.9 ng/ml. Associations between serum vitamin D concentration and clinical/inflammatory markers were assessed using Chi-square and t tests. MEASUREMENTS AND MAIN RESULTS: Data were collected for 148 children. The mean serum 25(OH)D concentration was 32.4 ng/ml (SD, 8.9). Seven percent (10 of 148) were vitamin D deficient, and 36% (53 of 148) were vitamin Dinsufficient. Among the pancreatic-sufficientpatients, 50% (14 of 28) were vitamin Dinsufficient/deficient, whereas among pancreatic-insufficientpatients, 41% (49 of 120) were vitamin Dinsufficient/deficient. Pseudomonas aeruginosa was a more common pathogen in the patients who were vitamin Dinsufficient/deficient (18 of 63 vs. 11 of 85, P = 0.018). There was no difference between vitamin D-sufficient versus -insufficient groups in terms of other bacterial colonization or inflammatory markers. CONCLUSIONS: Overall, vitamin Dinsufficiency is common among young children with CF. Vitamin Dinsufficiency is prevalent even in children who are pancreatic sufficient. In this population, vitamin Dinsufficiency is associated with a history of Pseudomonas colonization but not with classic markers of systemic inflammation.
Authors: Jessica A Alvarez; Elizabeth Y Chong; Douglas I Walker; Joshua D Chandler; Ellen S Michalski; Ruth E Grossmann; Karan Uppal; Shuzhao Li; Jennifer K Frediani; Rabindra Tirouvanziam; ViLinh T Tran; Vin Tangpricha; Dean P Jones; Thomas R Ziegler Journal: Metabolism Date: 2017-02-11 Impact factor: 8.694
Authors: N Dauletbaev; K Herscovitch; M Das; H Chen; J Bernier; E Matouk; J Bérubé; S Rousseau; L C Lands Journal: Br J Pharmacol Date: 2015-10 Impact factor: 8.739
Authors: Vin Tangpricha; Ellen M Smith; Jose Binongo; Suzanne E Judd; Thomas R Ziegler; Seth Walker; Rabindra Tirouvanziam; Susu M Zughaier; Moon Jeong Lee; Supavit Chesdachai; Wendy A Hermes; James F Chmiel; Amit Gaggar; Ruth E Grossmann; Patricia M Joseph; Jessica A Alvarez Journal: Contemp Clin Trials Commun Date: 2017-03-09